title: [Time of salvage treatment on sudden sensorineural hearing loss].
abstract: OBJECTIVE
  To explore the best time of intratympanic dexamethasone injection to treat sudden sensorineural hearing loss (SSNHL) as salvage therapy so that to improve the curative efficacy on sudden deafness at the utmost.
  
  
  METHODS
  A total of 192 patients with SSNHL were included in this study, among whom 63 cases received the systemic steroid therapy throughout the study, while the other ones were treated with systemic steroid as initial treatment and were given intratympanic steroid administration as salvage treatment starting at different time point. The salvage treatment started on the 3rd day after the beginning of the initial treatment for 29 cases, on the 7th day for 38 cases, on the 14th day for 43 cases, and 1 month later for 19 cases. All the patients were followed up for 2 months.
  
  
  RESULTS
  The recovery rates and total effective rates showed no statistically significant difference between the patients received only systemic steroid therapy and the ones received intratympanic steroid administration on the 3rd, 7th day and 1 month later after the initial treatment. The recovery rate and total effective rate exhibited statistically significant difference between the patients received intratympanic steroid administration since the 14th day after the initial treatment and the ones received only systemic steroid therapy, with the numerical value of P 0. 037 and 0. 034, respectively.
  
  
  CONCLUSIONS
  (1) As an initial management plan, the curative effects. between the intratympanic steroid administration and the systemic steroid therapy were not significantly different. (2) As a salvage treatment, intratympanic steroid was a better choice for patients who have not completely recover from ISSNHL after failure of initial management with systemic steroid only. (3) The best time point of salvage treatment with intratympanic steroid was about 2 weeks after initial management with systemic steroid.
authors.forename: Yangyun
authors.initials: Y
authors.lastname: Liu
authors.forename: Caixia
authors.initials: C
authors.lastname: Zhang
authors.forename: Hang
authors.initials: H
authors.lastname: Cao
authors.forename: Wen
authors.initials: W
authors.lastname: Jiang
authors.forename: Hui
authors.initials: H
authors.lastname: Yang
authors.forename: Zhengxian
authors.initials: Z
authors.lastname: Li
authors.forename: Qiong
authors.initials: Q
authors.lastname: Chen
authors.forename: Enge
authors.initials: E
authors.lastname: Chang
authors.forename: Tao
authors.initials: T
authors.lastname: Fan
authors.forename: Rong
authors.initials: R
authors.lastname: Hu
authors.forename: En
authors.initials: E
authors.lastname: Zhou
mesh_terms: D006319:Hearing Loss, Sensorineural / Q000188:drug therapy*; D003639:Hearing Loss, Sudden / Q000188:drug therapy*; D006801:Humans; D000069555:Injection, Intratympanic; D016879:Salvage Therapy; D013256:Steroids / Q000627:therapeutic use; D016896:Treatment Outcome; D014432:Tympanic Membrane
chemical_list: D013256:Steroids